Sweet综合征的发病机制及治疗进展  

Pathogenesis and therapeutic advances in Sweet syndrome

作　　者：宋智敏 温禾 钟华[1] 孙青[1] SONG Zhimin;WEN He;ZHONG Hua;SUN Qing(Department of Dermatology,Qilu Hospital of Shandong University,Jinan 250012,China)

机构地区：[1]山东大学齐鲁医院皮肤科,山东济南250012

出　　处：《中国麻风皮肤病杂志》2024年第6期446-449,共4页China Journal of Leprosy and Skin Diseases

摘　　要：Sweet综合征(Sweet syndrome, SS)是一种病因不明的炎症性嗜中性皮肤病,与感染、药物、肿瘤及自身免疫性疾病等相关。发病机制涉及中性粒细胞功能障碍、免疫失衡及遗传因素等。传统一线治疗首选系统应用糖皮质激素。近年来随着SS的研究取得一定进展,生物制剂及小分子靶向药物也有成功治疗SS的报道。本文就SS的发病机制及治疗进展作一综述。Sweet syndrome(SS)is an inflammatory neutrophilic dermatosis of unknown etiology,which is associated with infections,drugs,tumors and autoimmune diseases.The pathogenesis involves neutrophil dysfunction,immune imbalance and genetic factors.Traditional first-line treatment is preferred to the systematic application of glucocorticoids.In recent years,as the research of SS has made some progress,biologics and small molecule targeted drugs have also been reported to treat SS successfully.The pathogenesis and therapeutic progress of SS are reviewed in this paper.

关 键 词：SWEET综合征 急性发热性嗜中性皮病 发病机制 治疗 

分 类 号：R751[医药卫生—皮肤病学与性病学]